394 related articles for article (PubMed ID: 26371321)
1. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation.
Keleku-Lukwete N; Suzuki M; Otsuki A; Tsuchida K; Katayama S; Hayashi M; Naganuma E; Moriguchi T; Tanabe O; Engel JD; Imaizumi M; Yamamoto M
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12169-74. PubMed ID: 26371321
[TBL] [Abstract][Full Text] [Related]
2. Dietary supplementation with sulforaphane attenuates liver damage and heme overload in a sickle cell disease murine model.
Panda H; Keleku-Lukwete N; Kuga A; Fuke N; Suganuma H; Suzuki M; Yamamoto M
Exp Hematol; 2019 Sep; 77():51-60.e1. PubMed ID: 31404577
[TBL] [Abstract][Full Text] [Related]
3. Control of Oxidative Stress and Inflammation in Sickle Cell Disease with the Nrf2 Activator Dimethyl Fumarate.
Belcher JD; Chen C; Nguyen J; Zhang P; Abdulla F; Nguyen P; Killeen T; Xu P; O'Sullivan G; Nath KA; Vercellotti GM
Antioxid Redox Signal; 2017 May; 26(14):748-762. PubMed ID: 26914345
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 protects against furosemide-induced hepatotoxicity.
Qu Q; Liu J; Zhou HH; Klaassen CD
Toxicology; 2014 Oct; 324():35-42. PubMed ID: 24813929
[TBL] [Abstract][Full Text] [Related]
5. Nrf2-Keap1 defines a physiologically important stress response mechanism.
Motohashi H; Yamamoto M
Trends Mol Med; 2004 Nov; 10(11):549-57. PubMed ID: 15519281
[TBL] [Abstract][Full Text] [Related]
6. Nrf2 induces fibroblast growth factor 21 in diabetic mice.
Furusawa Y; Uruno A; Yagishita Y; Higashi C; Yamamoto M
Genes Cells; 2014 Dec; 19(12):864-78. PubMed ID: 25270507
[TBL] [Abstract][Full Text] [Related]
7. Nrf2 protects pancreatic β-cells from oxidative and nitrosative stress in diabetic model mice.
Yagishita Y; Fukutomi T; Sugawara A; Kawamura H; Takahashi T; Pi J; Uruno A; Yamamoto M
Diabetes; 2014 Feb; 63(2):605-18. PubMed ID: 24186865
[TBL] [Abstract][Full Text] [Related]
8. Genetic or pharmacologic amplification of nrf2 signaling inhibits acute inflammatory liver injury in mice.
Osburn WO; Yates MS; Dolan PD; Chen S; Liby KT; Sporn MB; Taguchi K; Yamamoto M; Kensler TW
Toxicol Sci; 2008 Jul; 104(1):218-27. PubMed ID: 18417483
[TBL] [Abstract][Full Text] [Related]
9. Mechanisms of NRF2 activation to mediate fetal hemoglobin induction and protection against oxidative stress in sickle cell disease.
Zhu X; Oseghale AR; Nicole LH; Li B; Pace BS
Exp Biol Med (Maywood); 2019 Feb; 244(2):171-182. PubMed ID: 30674214
[TBL] [Abstract][Full Text] [Related]
10. Nrf2 counteracts cholestatic liver injury via stimulation of hepatic defense systems.
Okada K; Shoda J; Taguchi K; Maher JM; Ishizaki K; Inoue Y; Ohtsuki M; Goto N; Sugimoto H; Utsunomiya H; Oda K; Warabi E; Ishii T; Yamamoto M
Biochem Biophys Res Commun; 2009 Nov; 389(3):431-6. PubMed ID: 19732748
[TBL] [Abstract][Full Text] [Related]
11. Toll-Like Receptor Signaling Induces Nrf2 Pathway Activation through p62-Triggered Keap1 Degradation.
Yin S; Cao W
Mol Cell Biol; 2015 Aug; 35(15):2673-83. PubMed ID: 26012548
[TBL] [Abstract][Full Text] [Related]
12. CACUL1/CAC1 Regulates the Antioxidant Response by Stabilizing Nrf2.
Kigoshi Y; Fukuda T; Endo T; Hayasaka N; Iemura S; Natsume T; Tsuruta F; Chiba T
Sci Rep; 2015 Aug; 5():12857. PubMed ID: 26238671
[TBL] [Abstract][Full Text] [Related]
13. Investigation of the effect of a panel of model hepatotoxins on the Nrf2-Keap1 defence response pathway in CD-1 mice.
Randle LE; Goldring CE; Benson CA; Metcalfe PN; Kitteringham NR; Park BK; Williams DP
Toxicology; 2008 Jan; 243(3):249-60. PubMed ID: 18078705
[TBL] [Abstract][Full Text] [Related]
14. Genetic versus chemoprotective activation of Nrf2 signaling: overlapping yet distinct gene expression profiles between Keap1 knockout and triterpenoid-treated mice.
Yates MS; Tran QT; Dolan PM; Osburn WO; Shin S; McCulloch CC; Silkworth JB; Taguchi K; Yamamoto M; Williams CR; Liby KT; Sporn MB; Sutter TR; Kensler TW
Carcinogenesis; 2009 Jun; 30(6):1024-31. PubMed ID: 19386581
[TBL] [Abstract][Full Text] [Related]
15. Loss of NRF2 function exacerbates the pathophysiology of sickle cell disease in a transgenic mouse model.
Zhu X; Xi C; Thomas B; Pace BS
Blood; 2018 Feb; 131(5):558-562. PubMed ID: 29255069
[TBL] [Abstract][Full Text] [Related]
16. Validation of the multiple sensor mechanism of the Keap1-Nrf2 system.
Takaya K; Suzuki T; Motohashi H; Onodera K; Satomi S; Kensler TW; Yamamoto M
Free Radic Biol Med; 2012 Aug; 53(4):817-27. PubMed ID: 22732183
[TBL] [Abstract][Full Text] [Related]
17. Nrf2 activation in myeloid cells and endothelial cells differentially mitigates sickle cell disease pathology in mice.
Keleku-Lukwete N; Suzuki M; Panda H; Otsuki A; Katsuoka F; Saito R; Saigusa D; Uruno A; Yamamoto M
Blood Adv; 2019 Apr; 3(8):1285-1297. PubMed ID: 31015205
[TBL] [Abstract][Full Text] [Related]
18. The Keap1-Nrf2 system as an in vivo sensor for electrophiles.
Uruno A; Motohashi H
Nitric Oxide; 2011 Aug; 25(2):153-60. PubMed ID: 21385624
[TBL] [Abstract][Full Text] [Related]
19. Identification and quantification of the basal and inducible Nrf2-dependent proteomes in mouse liver: biochemical, pharmacological and toxicological implications.
Walsh J; Jenkins RE; Wong M; Olayanju A; Powell H; Copple I; O'Neill PM; Goldring CE; Kitteringham NR; Park BK
J Proteomics; 2014 Aug; 108(100):171-87. PubMed ID: 24859727
[TBL] [Abstract][Full Text] [Related]
20. The Keap1-Nrf2 system prevents onset of diabetes mellitus.
Uruno A; Furusawa Y; Yagishita Y; Fukutomi T; Muramatsu H; Negishi T; Sugawara A; Kensler TW; Yamamoto M
Mol Cell Biol; 2013 Aug; 33(15):2996-3010. PubMed ID: 23716596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
